These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 34974859)
1. Multifunctional Nanoparticles Loaded with Vascular Endothelial Growth Factor Inhibitors and MED1 siRNA to Inhibit Breast Cancer Progression by Targeting Tumor-Associated Macrophages and Breast Cancer Cells. Wang S; Luo Z; Zhou X; Wang C; Luo Y; Yi N; Liao YL J Biomed Nanotechnol; 2021 Dec; 17(12):2364-2373. PubMed ID: 34974859 [TBL] [Abstract][Full Text] [Related]
2. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Song Y; Tang C; Yin C Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030 [TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Jadidi-Niaragh F; Atyabi F; Rastegari A; Mollarazi E; Kiani M; Razavi A; Yousefi M; Kheshtchin N; Hassannia H; Hadjati J; Shokri F Tumour Biol; 2016 Jun; 37(6):8403-12. PubMed ID: 26733167 [TBL] [Abstract][Full Text] [Related]
5. MED1 induces M2 polarization of tumor-associated macrophages to aggravate breast cancer. Shen Y; Zhou L; Xu M; Tan Z; Yao K; Wang W Genes Genomics; 2023 Dec; 45(12):1517-1525. PubMed ID: 37594664 [TBL] [Abstract][Full Text] [Related]
6. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526 [TBL] [Abstract][Full Text] [Related]
7. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514 [TBL] [Abstract][Full Text] [Related]
8. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487 [TBL] [Abstract][Full Text] [Related]
9. Optimization of multifunctional chitosan-siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in rats. He C; Yin L; Song Y; Tang C; Yin C Acta Biomater; 2015 Apr; 17():98-106. PubMed ID: 25662912 [TBL] [Abstract][Full Text] [Related]
10. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330 [TBL] [Abstract][Full Text] [Related]
11. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Han L; Tang C; Yin C Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049 [TBL] [Abstract][Full Text] [Related]
12. Investigation of the therapeutic efficacy of codelivery of psiRNA-vascular endothelial growth factor and pIL-4 into chitosan nanoparticles in the breast tumor model. Şalva E; Turan SO; Kabasakal L; Alan S; Özkan N; Eren F; Akbuğa J J Pharm Sci; 2014 Mar; 103(3):785-95. PubMed ID: 24357345 [TBL] [Abstract][Full Text] [Related]
13. Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment. Zhang X; Qin B; Wang M; Feng J; Zhang C; Zhu C; He S; Liu H; Wang Y; Averick SE; Vo NTN; Huang L; Liu W; Wang Z Int J Nanomedicine; 2022; 17():953-967. PubMed ID: 35280336 [TBL] [Abstract][Full Text] [Related]
14. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor. Yuan ZQ; Chen WL; You BG; Liu Y; Yang SD; Li JZ; Zhu WJ; Zhou XF; Liu C; Zhang XN J Control Release; 2017 Dec; 268():198-211. PubMed ID: 29061511 [TBL] [Abstract][Full Text] [Related]
15. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer. Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776 [TBL] [Abstract][Full Text] [Related]
16. Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy. Liu Y; Zhang D; Zhang Z; Liang X; Yang X; Ding N; Nie Y; Li C J Colloid Interface Sci; 2024 Mar; 657():598-610. PubMed ID: 38071809 [TBL] [Abstract][Full Text] [Related]
17. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594 [TBL] [Abstract][Full Text] [Related]
18. hTERT-molecular targeted therapy of ovarian cancer cells via folate-functionalized PLGA nanoparticles co-loaded with MNPs/siRNA/wortmannin. Ghareghomi S; Ahmadian S; Zarghami N; Hemmati S Life Sci; 2021 Jul; 277():119621. PubMed ID: 34004255 [TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. Ghalamfarsa G; Rastegari A; Atyabi F; Hassannia H; Hojjat-Farsangi M; Ghanbari A; Anvari E; Mohammadi J; Azizi G; Masjedi A; Yousefi M; Yousefi B; Hadjati J; Jadidi-Niaragh F J Cell Physiol; 2018 Oct; 233(10):7165-7177. PubMed ID: 29741783 [TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]